Drug-induced torsades de pointes in one patient with congenital long QT syndrome.
Although uncommon, torsades de pointes (TdP) associated with astemizole and/or erythromycin use have been reported previously. We describe a 30-year-old woman who had congenital prolongation of QT interval and TdP occurred after taking astemizole and erythromycin. Temporary cardiac pacing was successful in suppressing TdP. Prolongation of QT interval had good response to oral propranolol.
Hsieh
M H
MH
Department of Medicine, National Yang-Ming University, School of Medicine, Taipei, Taiwan, ROC.
Chen
S A
SA
Chiang
C E
CE
Tai
C T
CT
Lee
S H
SH
Wen
Z C
ZC
Chang
M S
MS
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016589:Astemizole / Q000009:adverse effects* / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography; D004917:Erythromycin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008133:Long QT Syndrome / Q000150:complications / Q000628:therapy*; D011433:Propranolol / Q000627:therapeutic use; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000150:complications / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D006634:Histamine H1 Antagonists; D004917:Erythromycin; D016589:Astemizole; D011433:Propranolol